Clinical and echocardiographic outcomes at 30 days and one year were similar between patients with bicuspid and tricuspid aortic stenosis following transcatheter aortic valve implantation (TAVI) with a self-expanding valve in a recent analysis from the TVT Registry. Researchers also noted that, in patients at increased surgical risk, TAVI for bicuspid aortic valve stenosis had acceptable safety outcomes with low complications rates.

LivaNova have presented the first data from the Perceval sutureless implant versus standard-aortic valve replacement (PERSIST-AVR) clinical study at the 100th Annual Meeting of the American Association of Thoracic Surgery (AATS), which took place online 22–23 May 2020. A press release from the company announced that the study demonstrated that its sutureless surgical aortic valve, Perceval, is a reliable and essential technology to treat aortic valve disease.

CeloNova BioSciences has announced that it has successfully completed enrolment into the COBRA REDUCE randomised controlled trial to evaluate the safety and efficacy of the Cobra PzF nanocoated coronary stent (NCS) in percutaneous coronary intervention (PCI) with 14-day dual antiplatelet therapy (DAPT). The study will compare it to US Food and Drug Administration (FDA)-approved drug-eluting stents (DES) with three or six months DAPT in 996 patients at high bleeding risk across 60 global sites.

According to research published in JACC: Heart Failure, patients with heart failure who experience low health literacy are at an increased risk of hospitalisation and mortality. A press release reports that this finding has significant clinical and public health implications and suggests that assessing and intervening upon an individual’s understanding of their own health could improve heart failure outcomes.

According to research published in JACC: Heart Failure, patients with heart failure who experience low health literacy are at an increased risk of hospitalisation and mortality. A press release reports that this finding has significant clinical and public health implications and suggests that assessing and intervening upon an individual’s understanding of their own health could improve heart failure outcomes.

Data from more than 1,000 patients presented during the virtual Society for Cardiovascular Angiography and Interventions (SCAI) 2020 Scientific Sessions (14–16 May, Eastern Time) demonstrates Impella (Abiomed) reduced in-hospital mortality when placed before a non-emergent percutaneous coronary intervention (PCI) is performed. According to a press release, the research found that, in the setting of high-risk PCI, when Impella is placed pre-PCI, it is associated with a 10 times reduction of in-hospital mortality, compared to when Impella is placed during “bailout” PCI.

Edwards Lifesciences has received the CE mark for the PASCAL transcatheter valve repair system for the treatment of European patients with tricuspid regurgitation.

A late-breaking clinical trial presented at the virtual Society for Cardiovascular Angiography and Interventions (SCAI) 2020 Scientific Sessions (14–16 May, Eastern Time) demonstrated strong long-term haemodynamic and safety outcomes for the Melody transcatheter pulmonary valve (Medtronic). Additionally, results from a second late-breaking trial—for the investigational Harmony transcatheter pulmonary valve (also Medtronic)—met its safety and efficacy endpoints for haemodynamic function at six months

A late-breaking clinical trial presented at the virtual Society for Cardiovascular Angiography and Interventions (SCAI) 2020 Scientific Sessions (14–16 May, Eastern Time) demonstrated strong long-term haemodynamic and safety outcomes for the Melody transcatheter pulmonary valve (Medtronic). Additionally, results from a second late-breaking trial—for the investigational Harmony transcatheter pulmonary valve (also Medtronic)—met its safety and efficacy endpoints for haemodynamic function at six months.

A study presented yesterday at the virtual Society for Cardiovascular Angiography and Interventions (SCAI) 2020 Scientific Sessions (14–16 May, Eastern Time) indicates that the addition of icosapent ethyl to statin therapy in patients with elevated triglycerides and increased cardiovascular risk is associated with reductions in first and repeat revascularisations.

The Society for Cardiovascular Angiography and Interventions (SCAI)has published a position statement addressing optimal percutaneous coronary intervention (PCI) treatment of patients with complex coronary artery disease. The position statement was presented today during the SCAI 2020 Scientific Sessions Virtual Conference and published in SCAI’s official journal, Catheterization and Cardiovascular Interventions.